According to research presented at ESC Congress 2024,1 women with endometriosis have a 20% greater risk of significant cardiac outcomes compared with women without endometriosis.
How the price of Lilly’s weight management drug could fuel its rivalry with Novo Nordisk
Eli Lilly’s highly anticipated weight loss rival Zepbound is set to hit shelves this year at a steep discount to Novo Nordisk’s Wegovy and with